Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Advanced or metastatic
gastroesophageal junction adenocarcinoma, often referred to as GEJ
adenocarcinoma, represents a particularly challenging and aggressive cancer
subtype. This malignancy originates in the cells lining the junction between
the stomach and the esophagus, known as the gastroesophageal junction (GEJ).
The tumor's epicenter is situated within the GEJ region in this type of
carcinoma. GEJ adenocarcinoma is associated with a substantial clinical burden
due to its high propensity for advancing to later stages and its generally poor
prognosis. The disease's progression to an advanced or metastatic state
intensifies the challenges patients and healthcare providers face. Metastatic
GEJ adenocarcinoma implies that the cancer has spread from its initial site to
other body parts, significantly reducing the chances of successful treatment
and long-term survival. Most patients diagnosed with GEJ adenocarcinoma present
with advanced stages of the disease. Subtle or nonspecific symptoms in the
early stages frequently lead to delayed diagnosis. Consequently, the potential
for successful curative treatment diminishes, and many patients are left with
limited treatment options. Factors contributing to the advanced presentation
include the tumor's aggressive nature and tendency to remain asymptomatic until
later stages. The Siewert classification is an essential framework medical
professionals use to categorize adenocarcinomas located within 5 cm of the GEJ.
This classification system divides GEJ adenocarcinomas into three distinct
types, each with unique characteristics and anatomical locations:
1. Type I
Adenocarcinoma: This type is situated 1–5 cm above the GEJ and is found in the
distal esophagus.
2. Type II
Adenocarcinoma: Characterized as true cardia carcinoma, this type is located
between 1 cm above and 2 cm below the GEJ.
3. Type III
Subcardial Carcinoma: This type is positioned 2–5 cm below the GEJ,
specifically in the subcardial region.
Diagnosing
advanced or metastatic gastroesophageal junction adenocarcinoma involves a
combination of clinical evaluation, imaging techniques, and often
histopathological confirmation. The treatment approach for advanced or
metastatic gastroesophageal junction adenocarcinoma is often multidisciplinary
and depends on factors like the tumor's stage, location, patient's overall
health, and individual preferences.
·
The incidence of Gastroesophageal junction
adenocarcinoma ranges from 2.8 to 3.9 per 100,000 population in the USA.
Thelansis’s “Advanced or Metastatic
Gastroesophageal Junction Adenocarcinoma Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2022 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Advanced
or Metastatic Gastroesophageal Junction Adenocarcinoma treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
KOLs insights
of Advanced or Metastatic Gastroesophageal Junction Adenocarcinoma across 8 MM
market from the centre of Excellence/ Public/ Private hospitals participated in
the study. Insights around current treatment landscape, epidemiology, clinical
characteristics, future treatment paradigm, and Unmet needs.
Advanced or Metastatic
Gastroesophageal Junction Adenocarcinoma Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment